Current status of selective estrogen receptor modulators (SERMs)

Cancer J. 2003 Jan-Feb;9(1):4-14. doi: 10.1097/00130404-200301000-00003.
No abstract available

Publication types

  • Review

MeSH terms

  • Benzopyrans / pharmacology
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / prevention & control*
  • Clinical Trials as Topic
  • Estradiol / analogs & derivatives*
  • Estradiol / pharmacology
  • Estrogen Antagonists / pharmacology
  • Estrogen Receptor Modulators / pharmacology
  • Female
  • Fulvestrant
  • Humans
  • Indoles / chemistry
  • Indoles / pharmacology
  • Molecular Structure
  • Piperidines / chemistry
  • Piperidines / pharmacology
  • Propionates / pharmacology
  • Selective Estrogen Receptor Modulators / chemistry
  • Selective Estrogen Receptor Modulators / pharmacology*
  • Tamoxifen / analogs & derivatives*
  • Tamoxifen / pharmacology
  • Thiophenes / chemistry
  • Thiophenes / pharmacology

Substances

  • 2-(4-hydroxyphenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl)-1H-indol-5-ol
  • Benzopyrans
  • Estrogen Antagonists
  • Estrogen Receptor Modulators
  • Indoles
  • Piperidines
  • Propionates
  • Selective Estrogen Receptor Modulators
  • Thiophenes
  • Tamoxifen
  • Fulvestrant
  • Estradiol
  • LY 353381
  • EM 800